AFT extends Maxigesic(R) IV license in South America

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN: ARBN 609 017 969 investor.relations@aftpharm.com





5 May 2021

AFT extends Maxigesic® IV license in South America.
AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces it has licensed Maxigesic
IV into Colombia, Peru, Chile, Ecuador, Bolivia, and Uruguay, extending the
medicine’s addressable market in Latin America and the Caribbean to 17 countries.
The agreement with Pharma Bavaria International builds on an agreement signed in
February 2020, that saw Maxigesic IV licensed to the German company in 12 countries
in Central America and the Caribbean including Panama, Costa Rica, El Salvador,
Honduras, Nicaragua, Guatemala, Belize, the Dominican Republic, Haiti, Trinidad &
Tobago, and Cuba.
Headquartered in Germany with a strong international focus, Pharma Bavaria has
dedicated itself to bringing novel pharmaceuticals to high growth regions. Following
this agreement, it now has the potential to take Maxigesic IV to a significant
population across these territories*.
AFT Pharmaceuticals Chief Executive Dr Hartley Atkinson said: “We are delighted to
extend our agreement with Pharma Bavaria. Latin American markets are significant
and growing with one recent report suggesting the market for pain management
medicines would grow at an average rate of 3.5% a year until 2027**.
“The agreement deals we have achieved over the last 12 months lifts the Maxigesic
IV coverage to over 100 countries. The focus now moves to accelerating registrations
and launches over the next 24 months.”
Pharma Bavaria’s Chief Executive Officer Dr Manuel Heim, added: “we are very
excited to extend our excellent collaboration with AFT to further territories in the LATAM
region with this innovative formulation, giving healthcare professionals new options in
hand for successful pain management. Maxigesic™ IV is a consequent add-on to our
existing portfolio, strengthening our focus in the therapeutic area of analgesics with
an added-value.”
Maxigesic IV (Paracetamol 1000mg+ Ibuprofen 300mg solution for infusion) is an
intravenous formulation developed as a line extension to Maxigesic tablets, for use
post-operatively in hospitals where patients cannot take an oral medicine. A major
Phase 3 clinical trial conducted in Texas and Maryland USA found that Maxigesic IV
provided significantly better pain relief than either paracetamol (acetaminophen) IV
or ibuprofen IV alone in the same doses.***
Following on from registration of the intravenous formulation in Australia and New
Zealand in mid-2019 and its registration in European markets in mid-2020, AFT has
continued its efforts to out-license the medicine around the world.

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN: ARBN 609 017 969 investor.relations@aftpharm.com

Released for and on behalf of AFT Pharmaceuticals by Chief Financial Officer
Malcolm Tubby.



For more information:
Investors Media
Dr Hartley Atkinson Richard Inder
Managing Director The Project
AFT Pharmaceuticals Tel: +64 21 645 643
Tel: +64 9488 0232

About AFT Pharmaceuticals
AFT is a growing multinational pharmaceutical company that develops, markets, and
distributes a broad portfolio of pharmaceutical products across a wide range of
therapeutic categories which are distributed across all major pharmaceutical
distribution channels: over the counter (OTC), prescription and hospital. Our product
portfolio comprises both proprietary and in-licensed products, and includes patented,
branded, and generic drugs. Our business model is to develop and in-license products
for sale by our own dedicated sales teams in our home markets of Australia and New
Zealand and in certain Southeast Asian markets, and to out-license our products to
local licensees and distributors to over 125 countries around the world. For more
information about the company, visit our website www.aftpharm.com
About Pharma Bavaria
Pharma Bavaria International Group distributes and promotes high-quality
pharmaceuticals with well-researched ingredients in more than 45 countries. With a
strong focus on growth regions such as the Middle East, Africa, South-East Asia, CIS
countries and other emerging economies Pharma Bavaria’s portfolio of prescription
medicines includes anti-infectives, analgesic/anti-allergic/anti-inflammatory, flu and
cold, gastroenterology, oncology, cardiology, and women’s healthcare brands and
is rounded off with a range of OTC products. For more information visit: www.pharma-
bavaria.com
References
* CIA, The World Fact Book.
** "LATAM Pain Management Drugs Market by Drug Class, Indication: Regional
Opportunity Analysis and Industry Forecast, 2019-2027
(https://www.globenewswire.com/news-release/2020/12/14/2144692/0/en/Insights-on-the-Pain-
Management-Drugs-LATAM-Market-to-2027-Opportunity-Analysis-and-Industry-Forecast.html)
*** Daniels SE et al. Efficacy and safety of an IV acetaminophen/ibuprofen
combination after bunionectomy. A randomized, double-blind, factorial, placebo-
controlled trial. Submitted for publication.